Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Podcast: Thermo Fisher Talks Regulatory Experience With Oncomine

Executive Summary

US FDA recently approved Oncomine Dx Target Test, the first multi-drug next-generation sequencing test made by Thermo Fisher Scientific. The test is a companion diagnostic for lung-cancer drugs made by Novartis and Pfizer, and the diagnostic company is looking to expand its partnership to other pharma companies.

Advertisement

Related Content

Diagnostics 2018: Steady Progress And The Big Get Bigger
US Approvals Analysis: Hits Just Keep On Coming. Can It Last?
First Expedited NGS Test Breaks Through FDA Review
A New York Minute: US FDA Leverages State's Health Department To Expedite NGS Reviews
Number To Know…23
Q&A: FDA Dx Reviewer's Tips For Next-Gen Sequencing Sponsors
Thermo Fisher Makes Final Push For ‘Universal’ Lung-Cancer Companion Dx
'App-A-Thon' Aims To Create PrecisionFDA Software Library To Advance Next-Gen Sequencing

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT105111

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel